Degos-Like Lesions Associated with Systemic Lupus Erythematosus

Min Soo Jang, Jong Bin Park, Myeong Hyeon Yang, Ji Yun Jang, Joon Hee Kim, Kang Hoon Lee, Geun Tae Kim, Hyun Hwangbo, Kee Suck Suh

Departments of Dermatology and Internal Medicine, Kosin University College of Medicine, Busan, Korea

Degos disease, also referred to as malignant atrophic papulosis, was first described in 1941 by Köhlmeier and was independently described by Degos in 1942. Degos disease is characterized by diffuse, papular skin eruptions with porcelain-white centers and slightly raised erythematous telangiectatic rims associated with bowel infarction. Although the etiology of Degos disease is unknown, autoimmune diseases, coagulation disorders, and vasculitis have all been considered as underlying pathogenic mechanisms. Approximately 15% of Degos disease have a benign course limited to the skin and no history of gastrointestinal or central nervous system (CNS) involvement. A 29-year-old female with history of systemic lupus erythematosus (SLE) presented with a 2-year history of asymptomatic lesions on the dorsum of all fingers and both knees. The patient had only skin lesions and no gastrointestinal or CNS vasculitis symptoms. Her skin lesions were umbilicated, atrophic porcelain-white lesions with a rim of erythema. On the basis of clinical, histologic, and laboratory findings, a diagnosis of Degos-like lesions associated with SLE was made. The patient had been treated for SLE for 7 years. Her treatment regimen was maintained over a 2 month follow-up period, and the skin lesions improved slightly with no development of new lesions. (Ann Dermatol 29(2) 215∼218, 2017)

Keywords-
Degos disease, Degos-like lesions, Systemic lupus erythematosus

INTRODUCTION

Degos disease is a rare systemic vaso-occlusive disorder. Degos-like lesions associated with systemic lupus erythematosus (SLE) are a type of vasculopathy. Almost all Degos-like lesions have the clinical pathognomonic appearance of porcelain-white, atrophic papules with peripheral telangiectatic erythema. Such lesions can be found in at least two distinctive clinical settings: (1) apparent idiopathic disease, either classic Degos disease or its benign variant; and (2) cutaneous manifestations in several connective tissue diseases such as SLE, antiphospholipid syndrome, dermatomyositis, and systemic sclerosis. The course, treatment, and prognosis of these diseases has substantially varied. To date, one case of systemic Degos disease with SLE has been reported in the Korean literature. Herein, we report the first case of cutaneous Degos-like lesions without systemic involvement associated with SLE in Korea.

CASE REPORT

A 29-year-old woman presented to our clinic with a two-year history of asymptomatic atrophic white lesions. Two years ago, the lesions began as pink dome-shaped papules on her dorsal fingers and knees bilaterally. These papules gradually turned into umbilicated, atrophic porcelain-white lesions with a rim of erythema. Seven years
ago, the patient was diagnosed with SLE and was being treated in a rheumatology clinic. On physical examination, atrophic, porcelain-white scars surrounded by an erythematous rim were seen on the dorsum of all fingers and both knees (Fig. 1). The patient also had a malar rash and arthritis, but did not have symptoms of gastrointestinal tract involvement or central nervous system (CNS) vasculitis, such as blurred vision and hemiparesis. Her neurological exam was unremarkable. On dermoscopy, a central whitish, structureless area surrounded by an erythematous rim of short vessels was seen (Fig. 2). Laboratory testing was positive for anti-nuclear antibody (1:1,280), anti-ds-DNA antibody, anti-smith antibody, anti-Ro antibody, and anti-La antibody, but negative for anticardiolipin immunoglobulin (Ig)G, anticardiolipin IgM, and lupus anticoagulant. Histologic findings showed hyperkeratosis, epidermal atrophy, and dermal sclerosis in the central portion. It also showed lymphocytic infiltration around vessels, fibrinoid necrosis of the vessel wall, and thrombus deposition in the lumen (Fig. 3). On the basis of these clinical, dermoscopic, laboratory, and histologic findings, the diagnosis of Degos-like lesions associated with SLE was made. The patient was being treated with hydroxychloroquine (300 mg/day), prednisolone (8 mg/day), and cyclosporine (50 mg/day) for seven years, and beraprost (20 μg/day) and pentoxifylline (400 mg/day) for 2 years for SLE. Because the patient’s skin lesions improved.
gradually during the two-month follow-up period, we continued her treatment as before without further intervention, and no new lesions developed.

DISCUSSION

Degos disease, also known as malignant atrophic papulosis, is a rare systemic vasculo-occlusive disorder first described by Köhlmeier in 1941 as erythematous papules with a central porcelain-white atrophic lesion. A combination of coagulopathy, endothelial cell damage, autoimmune disease, and vasculitis have been proposed as underlying pathogenic mechanisms, but none of these have been confirmed.

Degos disease is classified into two types by associated clinical symptoms and underlying disease. First, classic Degos disease has characteristic skin lesions and affects other organs with multiple limited infarcts. Skin lesions are usually the first manifestation of the disease, although its poor prognosis is the result of gastrointestinal and CNS involvement. With systemic involvement, the reported mean survival time is approximately 2 years, but it varies from less than 1 year to more than 12 years. Conversely, approximately 15% of Degos disease cases are a benign form often limited to the skin without gastrointestinal or CNS involvement. These cases generally exhibit long-term survival. Second, Degos-like lesions can occur in patients with connective tissue diseases such as SLE, antiphospholipid antibody syndrome, dermatomyositis, and systemic sclerosis. Because of the broad overlap in clinical features and histopathological findings indistinguishable from those of cutaneous lupus erythematosus in skin lesions of Degos disease, Ball et al. did not conceive of Degos disease as a specific disease, but as a distinctive pattern expressive of different pathologic processes.

SLE is a chronic multiorgan auto-immune inflammatory disease and skin lesions are the second most frequent clinical manifestation. Nonspecific disease-related skin lesions are frequently seen, usually in the active phase of the disease. Vasculopathy presenting as an acute or subacute manifestation of lupus can occur as Degos-like lesions and be etiologically implicated in the pathogenesis of Degos disease. In our patient, there was no evidence of abnormality in platelet aggregation or blood fibrinolytic activity. She was found to have positive anti-nuclear antibody (1:1,280), anti-Ro antibody, anti-La antibody, anti-ds-DNA antibody, and anti-smith antibody titers at the time of diagnosis. Considering that the presence of vasculitis in patients with SLE is associated with anti-La antibody, we assumed that our patient also had vasculitis, which can cause Degos-like skin lesions. By considering her clinical and laboratory findings, we suggested that her cutaneous Degos-like lesions were associated with SLE.

The skin lesions of Degos disease consist of three different evolution stages: (1) erythematous papules of onset; (2) erythematous papules with purple or necrotic centers with or without central crust; and (3) porcelain-white scars surrounded by an erythematous rim. Dermoscopic findings consist of three different patterns, each corresponding to a different evolution stage. Dermoscopically, in the early stages, papules are characterized by a combination of a reddish-to-purple background and purpuric dots. At the intermediate stage, papules display a targetoid pattern with necrotic centers surrounded by erythematous halos.
Finally, healed lesions have a whitish, structureless center surrounded by a rim of short, slightly curved vessels. Harvell et al. described sequential changes in the histology of Degos lesions. Early lesions show a superficial and deep perivascular lymphocytic infiltrate, interstitial mucin, and vascular interface dermatitis. Fully developed lesions typically show prominent lymphocytic vasculitis, intramural fibrin deposition, central epidermal atrophy, and a developing zone of papillary dermal sclerosis and mucin deposition. Late stage lesions often demonstrate a classic inverted wedge-shaped zone of sclerosis with an atrophic epidermis and a sparse lymphocytic infiltrate in the upper half of the dermis. Given features of the three different stages, the cutaneous lesions in our patient were late stage, as all lesions corresponded with the clinical, dermoscopic, and histologic findings of that stage. Currently, there is no consistently effective therapy for Degos disease, although Kim et al. reported that Degos-like lesions associated with Behçet’s disease improved after treatment with aspirin and dipyridamole. Heparin has been successfully used in the acute phase, although other fibrinolytic agents have been ineffective. Immunosuppression with corticosteroids or other agents may worsen skin lesions and complications of Degos disease. Other therapies without proven benefits include antibiotics, arsenic, chloroquine, azathioprine, methotrexate, phenylbutazone, and interferon. Our patient was treated with hydroxychloroquine, prednisolone, and cyclosporine for seven years, and with beraprost and pentoxifylline for two years for SLE. Her treatment was continued without modification, and her skin lesions slightly improved.

Considering all clinical, histological, and laboratory findings, we suggest that the cutaneous lesions in our patient were a reaction pattern. We suspect that her skin lesions were caused by peripheral arterial occlusion resulting from vasculitis associated with SLE. On the basis of our experience with this case, when pathognomonic Degos-like lesions that manifest with porcelain white scars surrounded by an erythematous rim occur, definitive diagnosis should be made after a careful clinical history and examinations that include physical, histological, and laboratory evaluation for SLE and other connective tissue diseases. Herein, we report a case of Degos-like lesions associated with SLE.

CONFLICTS OF INTEREST

The authors have nothing to disclose.

REFERENCES

1. Köhlmeier W. Multiple hautnekrosen bei thromboangiitis obliterans. Arch Dermatol Syphihol 1941;181:792-793.
2. Lipsker D. Malignant atrophic papulosis (Degos disease). In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K, editors. Fitzpatrick’s dermatology in general medicine. 8th ed. New York: McGraw Hill, 2012:2072-2076.
3. Lee JH, Ryu HJ, Park YB, Choi BY, Lee EY, Lee YJ, et al. A case of systemic lupus erythematosus with Degos’ disease. J Korean Rheum Assoc 2007;14:256-262.
4. Magro CM, Poe JC, Kim C, Shapiro L, Nuovo G, Crow MK, et al. Degos disease: a CSb-9/interferon-α-mediated endotheliopathy syndrome. Am J Clin Pathol 2011;135:599-610.
5. Theodoridis A, Makrantonaki E, Zouboulis CC. Malignant atrophic papulosis (Köhlmeier-Degos disease)-a review. Orphanet J Rare Dis 2013;8:10.
6. Subbiah P, Wijdicks E, Muentner M, Carter J, Connolly S. Skin lesion with a fatal neurologic outcome (Degos’ disease). Neurology 1996;46:636-640.
7. Tsao H, Busam K, Barnhill RL, Haynes HA. Lesions resembling malignant atrophic papulosis in a patient with dermatomyositis. J Am Acad Dermatol 1997;36:317-319.
8. Ball E, Newburger A, Ackerman AB. Degos’ disease: a distinctive pattern of disease, chiefly of lupus erythematosus, and not a specific disease per se. Am J Dermatopathol 2003;25:308-320.
9. Cardinalli C, Caproni M, Bernacchi E, Amato L, Fabbri P. The spectrum of cutaneous manifestations in lupus erythematosus—the Italian experience. Lupus 2000;9:417-423.
10. Ramos-Casals M, Nardi N, Lagrutta M, Brito-Zerón P, Bové A, Delgado G, et al. Vasculitis in systemic lupus erythematosus: prevalence and clinical characteristics in 670 patients. Medicine (Baltimore) 2006;85:95-104.
11. Anker JP, Kaminska-Winciorek G, Lallas A, Nicoletti S, Januszewski K, Mazzei ME, et al. The dermoscopic variability of Degos disease at different stages of progression. Dermatol Pract Concept 2014;4:59-61.
12. Harvell JD, Williford PL, White WL. Benign cutaneous Degos’ disease: a case report with emphasis on histopathology as papules chronologically evolve. Am J Dermatopathol 2001;23:116-123.
13. Kim YJ, Yun SJ, Lee SC, Lee JB. Degos disease associated with Behçet’s disease. Ann Dermatol 2015;27:235-236.
14. Melnik B, Hariry H, Vakilzadeh F, Gropp C, Sitzer G. Malignant atrophic papulosis (Köhlmeier-Degos disease). Failure to respond to interferon alpha-2a, pentoxifylline and aspirin. Hautarzt 2002;53:618-621.